BiosanaPharma

We are a biopharmaceutical company focused on reducing the manufacturing costs of (biosimilars of) Monoclonal Antibody (mAbs) biological drugs, in order to increase patient access to this important family of therapeutics. We have developed technology capable of reducing the COGS more than 10-fold, which allows healthy profitability even at 50% of the pricing of originator drugs. We are scaling up our platform to commercialize it to third parties and we are also developing our own pipeline of biosimilar products. We aim to become a global reference in the manufacturing of monoclonal antibody biologicals, biosimilars and biobetters.